Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.

Inclusion Criteria:

• Subject completed the preceding trial 243-07-001 (NCT00537485)

Exclusion Criteria:

• Subject discontinued from the preceding trial 243-07-001.
• Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 243-07-001.
• Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-07-001.
• Subject had persistent hallucination or delusion during trial 243-07-001.
• Subject has psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.
• Subject has orthostatic hypotension or a systolic blood pressure (SBP) <= 100 mmHg and has a decrease of SBP from spine to standing position >= 30 mmHg at baseline.
• Subject has a history of epilepsy, convulsion etc. during trial 243-07-001.
• Subject develops serious ECG abnormality at the baseline.
• Subject has QTc-interval >= 500 msec at the baseline or subject has an increase of QTc-interval >= 60 msec from the baseline in the trial 243-07-001 and has a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.
• Subject has a serum potassium level < 3.5 mEq/L at the end of the taper period in trial 243-07-001.
• Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L) at the end of the period in trial 243-07-001.
• Subject has BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at the end of the taper period in trial 243-07-001.
• Subject who plans pregnancy during the trial.
• Subject has dementia.
• Subject is unable to give consent.
• Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.

54 weeks